Esplugues De Llobregat

• A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec (RESPOND) Ended
  2023-505640-18-00 6 2021-09-02 Spinal Muscular Atrophy
• A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea … Ended
  2023-504156-10-00 5 2021-08-13 Plaque Psoriasis.
• "A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)" Ended
  2023-507146-91-00 5 2021-06-07 Duchenne Muscular Dystrophy (DMD)
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• A Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with … Ended
  2023-503973-39-00 5 2021-03-16 Complex Perianal Fistulas in Crohn's Disease
• A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo … Ended
  2023-507850-33-00 5 2021-02-05 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outc … Ended
  2024-510663-34-00 4 2021-01-29 Influenza, Human
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid … Ended
  2024-512469-15-00 9 2020-12-08 FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Po
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended
  2023-506253-38-00 5 2020-11-09 Migraine
• Investigation the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants with Angelman Syndrome Ended
  2024-514797-45-00 3 2020-08-25 Angelman Syndrome (AS)
• Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscu … Ended
  2023-509935-23-00 4 2020-08-21 Duchenne Muscular Dystrophy
• Long-term Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis Ended
  2023-503600-83-00 5 2020-05-27 Moderate to Severe Plaque Psoriasis
• Safety and pharmacokinetics of ceftolozane/tazobactam in pediatric participants with nosocomial pneumonia Ended
  2022-501110-56-00 3 2020-02-26 Nosocomial infection, Pneumonia
• A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents Ended
  2023-507904-30-00 3 2020-01-27 solid tumors
• A research study in children with low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin® once a day Ended
  2023-506829-11-00 5 2019-05-29 Growth Hormone Deficiency in children
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended
  2023-503898-38-00 5 2019-05-24 Atopic Dermatitis
• Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Ended
  2024-510751-34-00 5 2019-03-26 Gaucher's disease type I; Gaucher's disease type III
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv … Ended
  2023-508955-37-00 5 2018-10-10 Moderate to severe atopic dermatitis
• A Study Evaluating the Safety and Efficacy of KTE-X19 in pediatric and adolescent Subjects with Relapsed/Refractory B-precursor Acute Lympho … Ended
  2023-509440-97-00 3 2018-09-25 Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
• Study to test the safety and the initial efficacy of an investigational medicinal product, abbreviated as AAV9-hSGSH, in children with Sanfi … Ended
  2024-515835-31-00 7 2018-03-20 Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)
• A research study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patients Ended
  2024-514698-23-00 5 2017-05-15 Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Sk
• Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO) Ended
  2024-512730-15-00 4 2012-09-14 Systemic Lupus Erythematosus

Showing 289–312 of 317 trials